Featured Articles
-
Citeline Pharma R&D Review 2024: Pleasant Weather Ahead
5/16/2024
The pharma R&D environment continued its warming trend in 2024, with pipeline drugs rising 7.2% to hit a new high of 22,825. Oncology drugs accounted for 38% of all new drug candidates, while neurologicals came in second with a 12.7% share. Pfizer led the pack with 32 new candidates in the pipeline.
-
Optimizing Recruitment For Urgently Needed Vaccine
5/15/2024
Uncover how Citeline Connect helped a late-stage biotech sponsor expedite enrollment of a diverse population of eligible patients impacted by monkeypox for a large Phase 1 and Phase 2 trial of a next-generation vaccine.
-
Deal-Making Volume Slowed In 2023
5/15/2024
This report provides an overview of alliance, merger and acquisition, and financing deal activities across the global biopharma, medical device, and in vitro diagnostics industries in 2023, as reported by Biomedtracker.
-
Backup Sites: The Closers Of Clinical Trials
4/22/2024
With the rising complexity of trials and dwindling site availability, the adoption of backup sites has become increasingly commonplace, reflecting the industry's commitment to maximizing recruitment potential.
-
Pharma R&D Annual Review 2024
4/22/2024
As we reflect on the past year's accomplishments and challenges, our insights serve as a beacon for driving innovation, fostering collaboration, and advancing global healthcare outcomes.
-
Considerations For Plain Language Summaries
4/22/2024
Recent FDA emphasis on plain language underscores a shift towards greater transparency and patient understanding, highlighted in the joint FDA and Office for Human Research Protections (OHRP) draft guidance.
-
Diversity In Clinical Trials: Walking The Walk
4/22/2024
Discover why achieving true diversity demands more than rhetoric—requiring genuine engagement, cultural humility, and a commitment to understanding and addressing the unique needs of marginalized communities.
-
SCOPE 2024: Key Takeaways From A First-Time Attendee
3/15/2024
Sessions at SCOPE ran the industry gamut: patient-centric trial design; diversity, equity, and inclusion; AI; RWE; and much more. The common thread woven through many of these sessions? Quality data.
-
FDA Continues Diversity Push
3/15/2024
Review the FDA's revised 2016 diversity guidance, which establishes clear expectations and standardizes recommendations for gathering and reporting race and ethnicity data.
-
Rare Disease Prioritization Model And Landscape Analysis
3/15/2024
Uncover how a global pharmaceutical company seeking to identify promising indications among rare diseases to develop preclinical candidate molecules received an in-depth disease analysis to guide its strategic decision-making.